08:40 AM EDT, 10/28/2025 (MT Newswires) -- GSK (GSK) said Tuesday that its experimental therapy, GSK5764227, for treating pulmonary neuroendocrine carcinoma, a cancer category that includes small-cell lung cancer, has received orphan drug designation from the European Medicines Agency.

The drugmaker said the designation is based on early clinical data that showed durable responses in patients in an early-stage trial.